Cargando…

pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation

BACKGROUND: RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated nanostructured lipid carriers (RIPL-NLCs) can facilitate selective drug delivery to hepsin (Hpn)-expressing cancer cells, but they exhibit low stability in the blood. Generally, biocompatible and nontoxic poly(ethylene glycol) surface modificati...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Chang Hyun, Sa, Cheol-Ki, Goh, Min Su, Lee, Eun Seok, Kang, Tae Hoon, Yoon, Ho Yub, Battogtokh, Gantumur, Ko, Young Tag, Choi, Young Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204877/
https://www.ncbi.nlm.nih.gov/pubmed/30425481
http://dx.doi.org/10.2147/IJN.S184355
_version_ 1783366107335229440
author Kim, Chang Hyun
Sa, Cheol-Ki
Goh, Min Su
Lee, Eun Seok
Kang, Tae Hoon
Yoon, Ho Yub
Battogtokh, Gantumur
Ko, Young Tag
Choi, Young Wook
author_facet Kim, Chang Hyun
Sa, Cheol-Ki
Goh, Min Su
Lee, Eun Seok
Kang, Tae Hoon
Yoon, Ho Yub
Battogtokh, Gantumur
Ko, Young Tag
Choi, Young Wook
author_sort Kim, Chang Hyun
collection PubMed
description BACKGROUND: RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated nanostructured lipid carriers (RIPL-NLCs) can facilitate selective drug delivery to hepsin (Hpn)-expressing cancer cells, but they exhibit low stability in the blood. Generally, biocompatible and nontoxic poly(ethylene glycol) surface modification (PEGylation) can enhance NLC stability, although this may impair drug delivery and NLC clearance. To attain RIPL-NLC steric stabilization without impairing function, pH-sensitive cleavable PEG (cPEG) was grafted onto RIPL-NLCs (cPEG-RIPL-NLCs). METHODS: Various types of NLC formulations including RIPL-NLCs, PEG-RIPL-NLCs, and cPEG-RIPL-NLCs were prepared using the solvent emulsification–evaporation method and characterized for particle size, zeta potential (ZP), and cytotoxicity. The steric stabilization effect was evaluated by plasma protein adsorption and phagocytosis inhibition studies. pH-sensitive cleavage was investigated using the dialysis method under different pH conditions. Employing a fluorescent probe (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate [DiI]), in vitro drug delivery capacity of the cPEG-RIPL-NLCs under different pH conditions was also performed on Hpn-expressing SKOV3 cells and 3D-tumor spheroids. RESULTS: All prepared NLCs showed homogenous dispersion (<220 nm in size) with a negative ZP (−18 to −22 mV), except for positively charged RIPL-NLCs (~10 mV), revealing no significant cytotoxicity in either SKOV3 or RAW 264.7 cell lines. cPEG-RIPL-NLC protein adsorption was 1.75-fold less than that of RIPL-NLCs, and PEGylation significantly reduced the macrophage uptake. PEG detachment from the cPEG-RIPL-NLCs was pH-sensitive and time dependent. At 2 hours incubation, cPEG-RIPL-NLCs and PEG-RIPL-NLCs exhibited comparable cellular uptake at pH 7.4, whereas cPEG-RIPL-NLC uptake was increased over 2-fold at pH 6.5. 3D-spheroid penetration also demonstrated pH-sensitivity: at pH 7.4, cPEG-RIPL-NLCs could not penetrate deep into the spheroid core region during 2 hours, whereas at pH 6.5, high fluorescence intensity in the core region was observed for both cPEG-RIPL-NLC-and RIPL-NLC-treated groups. CONCLUSION: cPEG-RIPL-NLCs are good candidates for Hpn-selective drug targeting in conjunction with pH-responsive PEG cleavage.
format Online
Article
Text
id pubmed-6204877
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62048772018-11-13 pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation Kim, Chang Hyun Sa, Cheol-Ki Goh, Min Su Lee, Eun Seok Kang, Tae Hoon Yoon, Ho Yub Battogtokh, Gantumur Ko, Young Tag Choi, Young Wook Int J Nanomedicine Original Research BACKGROUND: RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated nanostructured lipid carriers (RIPL-NLCs) can facilitate selective drug delivery to hepsin (Hpn)-expressing cancer cells, but they exhibit low stability in the blood. Generally, biocompatible and nontoxic poly(ethylene glycol) surface modification (PEGylation) can enhance NLC stability, although this may impair drug delivery and NLC clearance. To attain RIPL-NLC steric stabilization without impairing function, pH-sensitive cleavable PEG (cPEG) was grafted onto RIPL-NLCs (cPEG-RIPL-NLCs). METHODS: Various types of NLC formulations including RIPL-NLCs, PEG-RIPL-NLCs, and cPEG-RIPL-NLCs were prepared using the solvent emulsification–evaporation method and characterized for particle size, zeta potential (ZP), and cytotoxicity. The steric stabilization effect was evaluated by plasma protein adsorption and phagocytosis inhibition studies. pH-sensitive cleavage was investigated using the dialysis method under different pH conditions. Employing a fluorescent probe (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate [DiI]), in vitro drug delivery capacity of the cPEG-RIPL-NLCs under different pH conditions was also performed on Hpn-expressing SKOV3 cells and 3D-tumor spheroids. RESULTS: All prepared NLCs showed homogenous dispersion (<220 nm in size) with a negative ZP (−18 to −22 mV), except for positively charged RIPL-NLCs (~10 mV), revealing no significant cytotoxicity in either SKOV3 or RAW 264.7 cell lines. cPEG-RIPL-NLC protein adsorption was 1.75-fold less than that of RIPL-NLCs, and PEGylation significantly reduced the macrophage uptake. PEG detachment from the cPEG-RIPL-NLCs was pH-sensitive and time dependent. At 2 hours incubation, cPEG-RIPL-NLCs and PEG-RIPL-NLCs exhibited comparable cellular uptake at pH 7.4, whereas cPEG-RIPL-NLC uptake was increased over 2-fold at pH 6.5. 3D-spheroid penetration also demonstrated pH-sensitivity: at pH 7.4, cPEG-RIPL-NLCs could not penetrate deep into the spheroid core region during 2 hours, whereas at pH 6.5, high fluorescence intensity in the core region was observed for both cPEG-RIPL-NLC-and RIPL-NLC-treated groups. CONCLUSION: cPEG-RIPL-NLCs are good candidates for Hpn-selective drug targeting in conjunction with pH-responsive PEG cleavage. Dove Medical Press 2018-10-23 /pmc/articles/PMC6204877/ /pubmed/30425481 http://dx.doi.org/10.2147/IJN.S184355 Text en © 2018 Kim et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Kim, Chang Hyun
Sa, Cheol-Ki
Goh, Min Su
Lee, Eun Seok
Kang, Tae Hoon
Yoon, Ho Yub
Battogtokh, Gantumur
Ko, Young Tag
Choi, Young Wook
pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation
title pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation
title_full pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation
title_fullStr pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation
title_full_unstemmed pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation
title_short pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation
title_sort ph-sensitive pegylation of ripl peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204877/
https://www.ncbi.nlm.nih.gov/pubmed/30425481
http://dx.doi.org/10.2147/IJN.S184355
work_keys_str_mv AT kimchanghyun phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation
AT sacheolki phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation
AT gohminsu phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation
AT leeeunseok phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation
AT kangtaehoon phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation
AT yoonhoyub phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation
AT battogtokhgantumur phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation
AT koyoungtag phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation
AT choiyoungwook phsensitivepegylationofriplpeptideconjugatednanostructuredlipidcarriersdesignandinvitroevaluation